Apr 12
|
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
|
Mar 20
|
10 NASDAQ Stocks with Biggest Upside
|
Mar 12
|
Insider Sell: CBO & EVP Thomas Kassberg Sells 11,509 Shares of Ultragenyx Pharmaceutical ...
|
Mar 11
|
Director Matthew Fust Sells 12,195 Shares of Ultragenyx Pharmaceutical Inc (RARE)
|
Mar 8
|
10 Biotech Stocks with Huge Potential
|
Jan 25
|
Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
|
Jan 9
|
After Golden Cross, Ultragenyx (RARE)'s Technical Outlook is Bright
|
Jan 7
|
Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones
|
Jan 4
|
Ultragenyx (RARE) Posts Update From AS Study of GTX-102
|
Jan 4
|
Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
|
Jan 3
|
Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome
|
Jan 2
|
Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
Dec 27
|
13 Most Promising Future Stocks To Buy According To Hedge Funds
|
Dec 21
|
Ultragenyx to Pay $6 Million to Settle Alleged False Medicare, Medicaid Claims
|
Dec 21
|
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
Dec 18
|
Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
|
Sep 7
|
Is Ultragenyx Pharmaceutical (RARE) Too Good to Be True? A Comprehensive Analysis of a ...
|
Aug 11
|
Henrietta Lacks' estate sues Ultragenyx over Mass.-made gene therapies
|
Aug 10
|
Henrietta Lacks' family sues Ultragenyx over use of HeLa cell line
|
Aug 8
|
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 41% Below Their Intrinsic Value Estimate
|